Cannabidiol (CBD) Listed as a Drug of Abuse by the Italian Health Ministry: Expert Opinion

Carla      Comacchio; Matteo      Balestrieri; Marco      Colizzi

doi:10.2174/012772316X295557240417104307

Note! Please note that this article is currently in the "Article in Press" stage and is not the final "Version of record". While it has been accepted, copy-edited, and formatted, however, it is still undergoing proofreading and corrections by the authors. Therefore, the text may still change before the final publication. Although "Articles in Press" may not have all bibliographic details available, the DOI and the year of online publication can still be used to cite them. The article title, DOI, publication year, and author(s) should all be included in the citation format. Once the final "Version of record" becomes available the "Article in Press" will be replaced by that.

Abstract

In August 2023, the Italian Health Ministry listed cannabidiol (CBD) as a drug of abuse. This rekindled the debate on the medical and non-medical use of cannabis. The most discussed topics are risks related to the use of cannabis, the decriminalization/legalization of recreational cannabis, and use of cannabis-based drugs for medical purposes. The decision to include CBD in the “Unique Text for drugs of abuse” (DPR.309/1990), along with the already included main psychoactive component of cannabis, delta-9-tetrahydrocannabinol (THC), is not particularly relevant to such ongoing discussions. Even when it comes to cannabis-based drugs for medical purposes, such a decision will have a minimum impact on CBD-based medical prescriptions. Instead, a high economic impact is expected on CBD-based products sold online or in specific shops, including the so-called “cannabis-light”, formally sold as a “technological product” for collection purposes but used as over-the-counter drugs for the treatment of several medical conditions. Cannabis-light products have reduced regular drug consumption by about 10%. Also, they are not entirely safe, as the actual content of THC may significantly differ from the one stated, carrying unexpected health risks. Further, CBD is likely not a drug with addictive potential; however, its uncontrolled use for medical purposes needs to be regulated as the court battles are ongoing.

[1]
Italian Health Ministry.  Law decree.,  Available from:
          https://www.gazzettaufficiale.it/eli/id/2023/08/21/23A04729/SG

[2]
Italian Health Ministry.  Law decree,  Available from: 
          https://www.gazzettaufficiale.it/eli/id/2020/10/15/20A05476/sg

[3]
Colizzi, M.; Bhattacharyya, S. Neurocognitive effects of cannabis: Lessons learned from human experimental studies.  Prog. Brain Res.,  2018, 242, 179-216.
 [http://dx.doi.org/10.1016/bs.pbr.2018.08.010] [PMID:  30471680]

[4]
Wright, S.; Metts, J. Recreational cannabinoid use: The hazards behind the “high”. J. Fam. Pract.,  2016, 65(11), 770-779.
 [PMID:  28087865]

[5]
Colizzi, M.; Ruggeri, M.; Bhattacharyya, S. Unraveling the intoxicating and therapeutic effects of cannabis ingredients on psychosis and cognition. Front. Psychol.,  2020, 11, 833.
 [http://dx.doi.org/10.3389/fpsyg.2020.00833] [PMID:  32528345]

[6]
Connor, J.P.; Stjepanović, D.; Le Foll, B.; Hoch, E.; Budney, A.J.; Hall, W.D. Cannabis use and cannabis use disorder. Nat. Rev. Dis. Primers,  2021, 7(1), 16.
 [http://dx.doi.org/10.1038/s41572-021-00247-4] [PMID:  33627670]

[7]
Assanangkornchai, S.; Kalayasiri, R.; Ratta-apha, W.; Tanaree, A. Effects of cannabis legalization on the use of cannabis and other substances. Curr. Opin. Psychiatry,  2023, 36(4), 283-289.
 [http://dx.doi.org/10.1097/YCO.0000000000000868] [PMID:  37185310]

[8]
McGinty, E.E.; Niederdeppe, J.; Heley, K.; Barry, C.L. Public perceptions of arguments supporting and opposing recreational marijuana legalization. Prev. Med.,  2017, 99, 80-86.
 [http://dx.doi.org/10.1016/j.ypmed.2017.01.024] [PMID:  28189806]

[9]
(a) World Health Organization (WHO) Drugs. Drugs (psychoactive): Cannabidiol (compound of cannabis). https://www.who.int/news-room/questions-and-answers/item/cannabidiol-(compound-of-cannabis)#:~:text=It%20has%20been%20widely%20reported,compounds%20of%20the%20cannabis%20plant; 
(b) Carrieri, V.; Madio, L.; Principe, F. Do-it-yourself medicine? the impact of light cannabis liberalization on prescription drugs. J. Health Econ.,  2020, 74, 102371. 
 [http://dx.doi.org/10.1016/j.jhealeco.2020.102371] [PMID:  32920244]

[10]
Pavlovic, R.; Nenna, G.; Calvi, L.; Panseri, S.; Borgonovo, G.; Giupponi, L.; Cannazza, G.; Giorgi, A. Quality traits of “cannabidiol oils”: Cannabinoids content, terpene fingerprint and oxidation stability of European commercially available preparations. Molecules,  2018, 23(5), 1230.
 [http://dx.doi.org/10.3390/molecules23051230] [PMID:  29783790]

[11]
Italian Health Ministry.  Recommendations for the doctor prescribing the herbal substance cannabis FM2 inflorescences.,  Available from: 
          https://www.salute.gov.it/imgs/C_17_pagineAree_4589_listaFile_itemName_2_file.pdf

Rights & Permissions Print Cite

Journal Information

For Authors

For Editors

For Reviewers

Explore Articles

Open Access

Open Access Articles

For Visitors

DOI https://dx.doi.org/10.2174/012772316X295557240417104307	Print ISSN 2772-316X
Publisher Name Bentham Science Publisher	Online ISSN 2772-3178

Current Social Sciences

Cannabidiol (CBD) Listed as a Drug of Abuse by the Italian Health Ministry: Expert Opinion

Abstract Play Pause

Related Books

Abstract